Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

1.500 +0.040 (+2.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 343,673
Open 1.460
Bid (Size) 1.490 (20)
Ask (Size) 1.520 (26)
Prev. Close 1.460
Today's Range 1.350 - 1.540
52wk Range 1.320 - 666.00
Shares Outstanding 198,742,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Agenus, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-99.54%
-99.54%
1 Month
-32.43%
-32.43%
3 Month
-74.21%
-74.21%
6 Month
-96.50%
-96.50%
1 Year
-99.58%
-99.58%

More News

Read More
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Shareholder Rights Law Firm Robbins LLP Encourages Allarity Therapeutics, Inc. Stockholders with Large Losses to Contact the Firm for Information About the ALLR Securities Class Action
From Robbins LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Agenus, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALLR CLASS ACTION REMINDER - Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Allarity Therapeutics, Inc. Securities Class Action
From Robbins LLP
Via GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
From Glancy Prongay & Murray LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sage, Outset Medical, Allarity, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALLR Lawsuit Reminder - Robbins LLP Reminds Stockholders of the Allarity Therapeutics, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Allarity Therapeutics, Inc. (ALLR) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.